Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition

作者
Qingxiang Lin,Alvin A. Morales-Giron,Conrad Sander,Jacquelyn M. Curtis,Haley Barnes,Parasvi S. Patel,Ferran Fece de la Cruz,Jakob Michael Riedl,Hiroyuki Matsubara,Hajime Nakamura,Andrew Scott Liss,Ryan Bruce Corcoran
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (11): 2279-2292 被引量:6
标识
DOI:10.1158/1078-0432.ccr-25-1788
摘要

PURPOSE: Oncogenic KRAS mutations are present in >90% of pancreatic ductal adenocarcinoma (PDAC), with KRASG12D being the most common. Mutant-selective KRASG12D inhibitors (KRASiG12D) have demonstrated promising initial clinical activity in KRASG12D-mutant PDAC. However, adaptive resistance to KRASi constrains efficacy in some tumor types, such as colorectal cancer, in which EGFR-mediated RAS-MAPK pathway reactivation can be targeted to improve response. Some studies have suggested a similar role for EGFR in PDAC, but the mechanisms of adaptive resistance to KRAS inhibition are unclear. EXPERIMENTAL DESIGN: Mechanisms of adaptive resistance to KRASiG12D were investigated in a panel of KRASG12D-mutant PDAC models. RESULTS: We observed receptor tyrosine kinase (RTK)-driven adaptive reactivation of RAS pathway signaling following KRASiG12D in PDAC models. EGFR was a primary driver of adaptive RAS-MAPK reactivation in some models but was limited to those with epithelial differentiation. Conversely, adaptive RAS-MAPK reactivation in models with mesenchymal differentiation was primarily driven by FGFR signaling. In clinical PDAC specimens from The Cancer Genome Atlas, EGFR and ERBB3 expression was highly correlated with the expression of epithelial markers, whereas the expression of FGFR1 and mesenchymal markers was correlated. Notably, a RAS(ON) multi-selective inhibitor, which inhibits both wild-type and mutant RAS, abrogated RAS-MAPK reactivation in combination with KRASi in both epithelial and mesenchymal models and led to more consistent antitumor activity compared with combinations of KRASi and EGFR blockade. CONCLUSIONS: In PDAC, adaptive RAS-MAPK reactivation following KRASG12D inhibition can be mediated by different RTKs and influenced by cell state. Combinations of mutant-selective KRASi and RAS(ON) multi-selective inhibitors may represent a promising universal strategy to surmount adaptive resistance in patients with PDAC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
天明发布了新的文献求助10
2秒前
2秒前
Karma完成签到,获得积分10
3秒前
4秒前
111完成签到,获得积分10
4秒前
含蓄平蓝完成签到 ,获得积分10
4秒前
LIUJIAWEI发布了新的文献求助10
5秒前
jachin完成签到 ,获得积分10
6秒前
简单山水发布了新的文献求助10
7秒前
7秒前
7秒前
李茗慧完成签到 ,获得积分10
7秒前
忆修完成签到,获得积分10
9秒前
Hello的应助被zhu采纳,获得10
9秒前
毕业就摆烂完成签到,获得积分20
10秒前
朴素的伟诚完成签到,获得积分10
12秒前
yanxiaoling发布了新的文献求助10
12秒前
12秒前
申晨曦完成签到 ,获得积分10
12秒前
12秒前
zzzxl完成签到,获得积分10
12秒前
Hello的应助被小艾同学采纳,获得10
13秒前
沉默诗兰完成签到,获得积分10
13秒前
王君青见完成签到,获得积分10
14秒前
11完成签到,获得积分10
16秒前
16秒前
song完成签到 ,获得积分10
16秒前
王敏完成签到 ,获得积分10
16秒前
山里万重完成签到,获得积分10
17秒前
Juvenilesy的应助被傻傻的起眸采纳,获得10
17秒前
17秒前
17秒前
和谐的寒风完成签到,获得积分20
17秒前
王长长完成签到,获得积分10
18秒前
18秒前
英姑的应助被brokey采纳,获得10
19秒前
xuhangming完成签到,获得积分20
21秒前
21秒前
jack完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568